Veeva Systems Inc. VEEV
Healthcare · Health Information Services · United States · S&P 500
Based on the available data, Veeva Systems Inc. gets an algorithmic score of 74/100. It trades at 278.57 $, with a bullish technical trend (RSI 64.8) and 42.7% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High net margin (29.3%): pricing power / competitive advantage.
- Sustained revenue growth (14.0% compound annual).
- Low-debt balance sheet.
Weaknesses
- —
Fundamentals
| P/E | 45.67 |
| Forward P/E | 27.18 |
| PEG | 1.21 |
| P/B | 6.21 |
| EV/EBITDA | 35.35 |
| P/S | 13.04 |
| ROE % | 14.42 |
| ROA % | 7.58 |
| Gross margin % | 74.96 |
| Operating margin % | 29.64 |
| Net margin % | 29.34 |
| Revenue growth % (y/y) | 17.60 |
| Earnings growth % (y/y) | 39.50 |
| Revenue CAGR % | 14.03 |
| Earnings CAGR % | 23.06 |
| Debt/Equity % | 2.04 |
| Current ratio | 5.46 |
| FCF yield % | 3.14 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +0.7 % |
| 3 months | +57.0 % |
| 6 months | +58.3 % |
| YTD | +26.9 % |
| 1 year | -4.0 % |
| 3 years | +37.1 % |
| 5 years | -6.7 % |
Risk
| 1-year volatility | 42.7 % |
| Beta | 0.73 |
| 5-year max drawdown | -53.5 % |
| Sharpe 1A | 0.02 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.